Peptonic Medical AB (publ) (“Peptonic” or the “Company”) publishes today, February 27, 2026, its year-end report for 2025. Key figures for the Group – Fourth
Peptonic Medical AB (publ) (“Peptonic”) announces the appointment of Daniel Rudeklint as interim CEO with immediate effect. Daniel Rudeklint replaces Anna Linton as CEO. Daniel
Peptonic Medical AB (publ) (the “Company”) announces that the Company has terminated its agreement with Mangold Fondförvaltning AB regarding the assignment as liquidity provider. The
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
